CRL Relative Valuation
CRL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRL is overvalued; if below, it's undervalued.
Historical Valuation
Charles River Laboratories International Inc (CRL) is now in the Undervalued zone, suggesting that its current forward PE ratio of 15.48 is considered Undervalued compared with the five-year average of 22.64. The fair price of Charles River Laboratories International Inc (CRL) is between 171.21 to 283.42 according to relative valuation methord. Compared to the current price of 162.53 USD , Charles River Laboratories International Inc is Undervalued By 5.07%.
Relative Value
Fair Zone
171.21-283.42
Current Price：162.53
5.07%
Undervalued
15.48
PE
1Y
3Y
5Y
Trailing
Forward
10.98
EV/EBITDA
Charles River Laboratories International Inc. (CRL) has a current EV/EBITDA of 10.98. The 5-year average EV/EBITDA is 15.20. The thresholds are as follows: Strongly Undervalued below 7.18, Undervalued between 7.18 and 11.19, Fairly Valued between 19.21 and 11.19, Overvalued between 19.21 and 23.22, and Strongly Overvalued above 23.22. The current Forward EV/EBITDA of 10.98 falls within the Undervalued range.
13.41
EV/EBIT
Charles River Laboratories International Inc. (CRL) has a current EV/EBIT of 13.41. The 5-year average EV/EBIT is 18.43. The thresholds are as follows: Strongly Undervalued below 9.32, Undervalued between 9.32 and 13.87, Fairly Valued between 22.98 and 13.87, Overvalued between 22.98 and 27.53, and Strongly Overvalued above 27.53. The current Forward EV/EBIT of 13.41 falls within the Undervalued range.
162.74
PS
Charles River Laboratories International Inc. (CRL) has a current PS of 162.74. The 5-year average PS is 5.34. The thresholds are as follows: Strongly Undervalued below -33.67, Undervalued between -33.67 and -14.17, Fairly Valued between 24.85 and -14.17, Overvalued between 24.85 and 44.36, and Strongly Overvalued above 44.36. The current Forward PS of 162.74 falls within the Strongly Overvalued range.
13.65
P/OCF
Charles River Laboratories International Inc. (CRL) has a current P/OCF of 13.65. The 5-year average P/OCF is 17.44. The thresholds are as follows: Strongly Undervalued below 7.02, Undervalued between 7.02 and 12.23, Fairly Valued between 22.65 and 12.23, Overvalued between 22.65 and 27.86, and Strongly Overvalued above 27.86. The current Forward P/OCF of 13.65 falls within the Historic Trend Line -Fairly Valued range.
18.94
P/FCF
Charles River Laboratories International Inc. (CRL) has a current P/FCF of 18.94. The 5-year average P/FCF is 28.33. The thresholds are as follows: Strongly Undervalued below 12.00, Undervalued between 12.00 and 20.16, Fairly Valued between 36.49 and 20.16, Overvalued between 36.49 and 44.65, and Strongly Overvalued above 44.65. The current Forward P/FCF of 18.94 falls within the Undervalued range.
Charles River Laboratories International Inc (CRL) has a current Price-to-Book (P/B) ratio of 2.35. Compared to its 3-year average P/B ratio of 2.98 , the current P/B ratio is approximately -21.01% higher. Relative to its 5-year average P/B ratio of 4.37, the current P/B ratio is about -46.22% higher. Charles River Laboratories International Inc (CRL) has a Forward Free Cash Flow (FCF) yield of approximately 0.07%. Compared to its 3-year average FCF yield of 4.54%, the current FCF yield is approximately -98.50% lower. Relative to its 5-year average FCF yield of 3.87% , the current FCF yield is about -98.25% lower.
2.35
P/B
Median3y
2.98
Median5y
4.37
0.07
FCF Yield
Median3y
4.54
Median5y
3.87
Competitors Valuation Multiple
The average P/S ratio for CRL's competitors is 51.90, providing a benchmark for relative valuation. Charles River Laboratories International Inc Corp (CRL) exhibits a P/S ratio of 162.74, which is 213.55% above the industry average. Given its robust revenue growth of -0.49%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRL decreased by 18.25% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -94.87 to -97.52.
The secondary factor is the Revenue Growth, contributed -0.49%to the performance.
Overall, the performance of CRL in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Charles River Laboratories International Inc (CRL) currently overvalued or undervalued?
What is Charles River Laboratories International Inc (CRL) fair value?
How does CRL's valuation metrics compare to the industry average?
What is the current P/B ratio for Charles River Laboratories International Inc (CRL) as of Nov 19 2025?
What is the current FCF Yield for Charles River Laboratories International Inc (CRL) as of Nov 19 2025?
What is the current Forward P/E ratio for Charles River Laboratories International Inc (CRL) as of Nov 19 2025?